Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY)
CUSIP: 75943R102
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 4,389,099
- Total 13F shares
- 129,294,786
- Share change
- -858,538
- Total reported value
- $1,623,964,520
- Put/Call ratio
- 82%
- Price per share
- $12.56
- Number of holders
- 159
- Value change
- -$20,848,790
- Number of buys
- 91
- Number of sells
- 62
Quarterly Holders Quick Answers
What is CUSIP 75943R102?
CUSIP 75943R102 identifies RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 75943R102:
Top shareholders of RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD |
13F
|
Company |
636%
|
27,904,963
|
$459,594,741 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
239%
|
10,499,514
|
$172,926,995 | — | 31 Mar 2023 | |
| FMR LLC |
13F
|
Company |
201%
|
8,806,991
|
$145,051,147 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
181%
|
7,935,690
|
$130,700,814 | — | 31 Mar 2023 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
156%
|
6,862,960
|
$113,034,000 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
134%
|
5,880,281
|
$96,848,228 | — | 31 Mar 2023 | |
| Casdin Capital, LLC |
13F
|
Company |
130%
|
5,698,574
|
$93,855,514 | — | 31 Mar 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
98%
|
4,300,826
|
$70,834,000 | — | 31 Mar 2023 | |
| Bellevue Group AG |
13F
|
Company |
95%
|
4,172,600
|
$68,722,722 | — | 31 Mar 2023 | |
| EcoR1 Capital, LLC |
13F
|
Company |
95%
|
4,163,824
|
$68,578,181 | — | 31 Mar 2023 | |
| BVF INC/IL |
13F
|
Company |
71%
|
3,120,521
|
$51,394,981 | — | 31 Mar 2023 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
61%
|
2,670,197
|
$43,978,145 | — | 31 Mar 2023 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
51%
|
2,221,580
|
$36,590,000 | — | 31 Mar 2023 | |
| Boxer Capital, LLC |
13F
|
Company |
49%
|
2,169,132
|
$35,726,000 | — | 31 Mar 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
44%
|
1,943,097
|
$32,002,807 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
40%
|
1,754,530
|
$28,897,120 | — | 31 Mar 2023 | |
| Artal Group S.A. |
13F
|
Company |
38%
|
1,673,743
|
$27,567,000 | — | 31 Mar 2023 | |
| NORGES BANK |
13F
|
Company |
37%
|
1,613,784
|
$26,579,022 | — | 31 Mar 2023 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
36%
|
1,582,251
|
$26,059,674 | — | 31 Mar 2023 | |
| Alphabet Inc. |
13F
|
Company |
36%
|
1,568,753
|
$25,837,362 | — | 31 Mar 2023 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
34%
|
1,485,914
|
$24,473,004 | — | 31 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
32%
|
1,399,099
|
$23,043,161 | — | 31 Mar 2023 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
28%
|
1,235,795
|
$20,351,153 | — | 31 Mar 2023 | |
| MPM BioImpact LLC |
13F
|
Company |
28%
|
1,225,634
|
$20,186,192 | — | 31 Mar 2023 | |
| S.c.a. Candriam |
13F
|
Individual |
28%
|
1,238,872
|
$18,780,694 | — | 31 Mar 2023 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
20%
|
886,542
|
$14,601,346 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
20%
|
872,422
|
$14,368,790 | — | 31 Mar 2023 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
19%
|
850,500
|
$14,007,735 | — | 31 Mar 2023 | |
| Finepoint Capital LP |
13F
|
Company |
19%
|
846,270
|
$13,938,067 | — | 31 Mar 2023 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
18%
|
770,000
|
$12,681,900 | — | 31 Mar 2023 | |
| Rock Springs Capital Management LP |
13F
|
Company |
15%
|
673,966
|
$11,100,220 | — | 31 Mar 2023 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
15%
|
658,127
|
$10,839,352 | — | 31 Mar 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
15%
|
653,882
|
$10,769,437 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
14%
|
625,903
|
$10,308,622 | — | 31 Mar 2023 | |
| Nextech Invest Ltd. |
13F
|
Company |
14%
|
625,485
|
$10,301,738 | — | 31 Mar 2023 | |
| BESSEMER GROUP INC |
13F
|
Company |
13%
|
584,463
|
$9,626,000 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
13%
|
562,134
|
$9,258,347 | — | 31 Mar 2023 | |
| HARVARD MANAGEMENT CO INC |
13F
|
Company |
12%
|
541,124
|
$8,912,312 | — | 31 Mar 2023 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
10%
|
443,626
|
$7,306,520 | — | 31 Mar 2023 | |
| BAILLIE GIFFORD & CO |
13F
|
Company |
9.5%
|
415,663
|
$6,845,970 | — | 31 Mar 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
8.6%
|
376,001
|
$6,192,736 | — | 31 Mar 2023 | |
| CITIGROUP INC |
13F
|
Company |
8.1%
|
356,112
|
$5,865,165 | — | 31 Mar 2023 | |
| HARBOURVEST PARTNERS LLC |
13F
|
Company |
6.8%
|
296,402
|
$4,881,741 | — | 31 Mar 2023 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
6.7%
|
294,726
|
$4,854,137 | — | 31 Mar 2023 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
6.5%
|
284,000
|
$4,677,480 | — | 31 Mar 2023 | |
| Woodline Partners LP |
13F
|
Company |
6.3%
|
275,000
|
$4,529,250 | — | 31 Mar 2023 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
6.1%
|
268,108
|
$4,415,739 | — | 31 Mar 2023 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
5.8%
|
254,897
|
$4,198,154 | — | 31 Mar 2023 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
5.7%
|
250,937
|
$4,133,000 | — | 31 Mar 2023 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
5.5%
|
240,381
|
$3,950,553 | — | 31 Mar 2023 |
Institutional Holders of Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) as of Q2 2023
As of 30 Jun 2023,
Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
129,294,786 shares.
The largest 10 holders included
SB INVESTMENT ADVISERS (UK) LTD, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, Casdin Capital, LLC, JPMORGAN CHASE & CO, Bellevue Group AG, EcoR1 Capital, LLC, and ArrowMark Colorado Holdings LLC.
This page lists
159
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
155
Q2 2023 holders
159
Holder diff
4
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.